Sean Wharton

Sean Wharton

doctor Canada

Sean Wharton is the director of the Wharton Medical Clinic in Burlington, recognized for his expertise in obesity and diabetes management. He recently expressed optimism about the new oral GLP-1 medication, orforglipron, stating it could make treatment more accessible to underserved populations worldwide.

Global Media Ratings
Dominance
0.00%
Persistence
0 wks
Reach
0
Power
0$
Sentiment
0.00
Countries Mentioned

No country-level mention data available.

Interactive World Map

Each country's color is based on "Mentions" from the table above.

Recent Mentions

Liechtenstein Liechtenstein: Sean Wharton is the lead author of the study and medical director of the Wharton Medical Clinic in Canada. 8

O Estado de S. Paulo (Estadão): Wegovy: dose tripla potencializa perda de peso e se aproxima de resultados de Mounjauro; veja dados

Australia Australia: Dr. Sean Wharton is the director of the Wharton Medical Clinic in Burlington, Ontario, who enrolled patients in Lilly’s study of orforglipron for obesity. 8

The Sydney Morning Herald: Eli Lilly weight-loss pill orforglipron ‘works as well as Ozempic’ in new trial

Liechtenstein Liechtenstein: Sean Wharton, director of the Wharton Medical Clinic in Burlington, expressed hope that a pill could potentially bring GLP-1 treatment to underserved populations worldwide. 8

O Estado de S. Paulo (Estadão): Pílula diária de GLP-1, classe do Ozempic, apresenta dados animadores de controle do peso e diabetes